The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines - PubMed
a day ago
- #drug-delivery
- #lipid-nanoparticles
- #nucleic-acid-therapeutics
- Nucleic acid-based therapies show promise for treating diseases like cancers, rare diseases, and infectious diseases.
- Challenges include high molecular weight, limited cellular uptake, and susceptibility to enzymatic degradation.
- Lipid nanoparticles (LNPs) are a leading delivery method due to biocompatibility, efficiency, and customizable design.
- LNPs have been successfully used in FDA-approved siRNA drug Onpattro®.
- The review discusses advancements in LNP design, delivery mechanisms, and clinical applications.
- LNPs are compared with other carriers like exosomes, polymers, and inorganic nanoparticles.